Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: A case report.

ABSTRACT:

Background

Immunocompromised patients receiving B-cell-depleting therapies are at increased risk of persistent SARS-CoV-2 infection, with many experiencing fatal outcomes. We report a successful outcome in a patient with rheumatoid arthritis (RA) on rituximab diagnosed with COVID-19 in July 2020 with persistent infection for over 245 days.

Results

The patient received numerous treatment courses for persistent COVID-19 infection, including remdesivir, baricitinib, immunoglobulin and high doses of corticosteroids followed by a prolonged taper due to persistent respiratory symptoms and cryptogenic organizing pneumonia. Her clinical course was complicated by Pseudomonas aeruginosa sinusitis with secondary bacteremia, and cytomegalovirus (CMV) viremia and pneumonitis. SARS

SUBMITTER: Overbeck V 

PROVIDER: S-EPMC10784163 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature